Design, statistical analysis and sample size calculation of a phase IIb/III study of linagliptin versus voglibose and placebo

Trials

Volumn 10, Issue , 2009, Pages 82-

  Horie, Yoshiharu ^a,b   Hayashi, Naoyuki ^b   Dugi, Klaus ^c   Takeuchi, Masahiro ^a  

^a KITASATO UNIVERSITY   (Japan)

^b NIPPON BOEHRINGER INGELHEIM CO LTD   (Japan)

^c BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; LINAGLIPTIN; ORAL ANTIDIABETIC AGENT; PLACEBO; UNCLASSIFIED DRUG; VOGLIBOSE;

ADULT; AGED; ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; STATISTICAL ANALYSIS;

DATA INTERPRETATION, STATISTICAL; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DOUBLE-BLIND METHOD; HUMANS; HYPOGLYCEMIC AGENTS; INOSITOL; PLACEBOS; PROSPECTIVE STUDIES; RESEARCH DESIGN; SAMPLE SIZE;

EID: 70350113620     PISSN: 17456215     EISSN: 17456215     Source Type: Journal    
DOI: 10.1186/1745-6215-10-82     Document Type: Article

References (20)

1. World Health Organization. , http://www.who.int/diabetes/facts
2. Ministry of Health, Labour and Welfare (Japan) Diabetes Survey 2006,
3. Hüttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol 1356, 48:1171-1178.
4. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazo lin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Exp Ther 2008, 325:175-182. 10.1211/jpp/61.01.0008, 18223196.
5. Fuchs H, Tillement JP, Urien S, Greischel A, Roth W. Concentration-dependent plasma protein binding of the novel DPP-4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans. J Pharm Pharmacol 2009, 61:55-62. 10.1111/j.1463-1326.2009.01046.x, 19126297.
6. Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab 2009, 11:786-94.
7. Brunetti P. The lean patient with type 2 diabetes: characteristics and therapy challenge. Int J Clin Pract Suppl 2007, 153:3-9. 10.1016/S0010-7824(03)00140-9, 17594388.
8. de Visser SJ, Uchida N, van Vliet-Daskalopoulou E, Fukazawa I, van Doorn MB, Heuvel MW, Machielsen CS, Uchida E, Cohen AF. Pharmacokinetic differences between Caucasian and Japanese subjects after single and multiple doses of a potential combined oral contraceptive (Org 30659 and EE). Contraception 2003, 68:195-202. 10.1016/j.clpt.2005.06.013, 14561540.
9. Lee E, Ryan S, Birmingham B, Zalikowski J, March R, Ambrose H, Moore R, Lee C, Chen Y, Schneck D. Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin Pharmacol Ther 2005, 78:330-41.
10. Pharmaceutical and Medical Devices Agency (PMDA) Points to Be Considered by the Review Staff Involved in the Evaluation Process of New Drug. 2008, , http://www.pmda.go.jp/english/service/pdf/points.pdf
11. Kanada S, Watada H, Hayashi N, Sarashina A, Taniguchi A, Horie Y, Dugi KA. Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of BI 1356 (proposed tradename ONDERO), a Dipeptidyl Peptidase 4 Inhibitor, in Japanese Patients with Type 2 Diabetes [abstract]. Diabetes 2008, 57(Suppl 1):A97. (533-P).
12. Ishii H, Bradley C, Riazi A, Barendse S, Yamamoto T. The Japanese version of the Diabetes Treatment Satisfaction Questionnaire (DTSQ) translation and clinical evaluation. J Clin Exp Med 2000, 192:809-814.
13. Zelen M. The randomization and stratification of patients to clinical trials. J Chronic Dis 1974, 27:365-75.
14. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Statistical principles for clinical trials 1998,
15. Hochberg Y, Tamhane AC. Multiple Comparison Procedures 1987, New York: John Wiley & Sons, Inc.
16. Kawamori R, Toyota T, Oka Y, Yamada A, Iwamoto Y, Tajima N, Kikkawa R, Seino Y, Matsuzawa Y, Nawata H, Hotta N. Improvement of glycaemic control following 12-weeks treatment with miglitol in Japanese type 2 diabetes: a double-blind, randomized, placebo- and voglibose-controlled trial [abstract]. Diabetes Metabolism 2003, 29:4s263.
17. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Safety evaluation of new drugs expected to be long-used for nonfatal diseases in the clinical development. 1996, 5:32-40.
18. Molinaro RJ. Targeting HbA1c: standardization and clinical laboratory measurement. MLO Med Lab Obs 2008, 40:10-4. 16-9., 10.2337/diacare.24.3.606, 18314846.
19. Manley S. Haemoglobin A1c--a marker for complications of type 2 diabetes: the experience from the UK Prospective Diabetes Study (UKPDS). Clin Chem Lab Med 2003, 41:1182-1190.
20. Bell DS. Ethics in diabetic clinical trials. Diabetes Care 2001, 24:606-607.